HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
ID: 343550Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/343550

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-006.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of therapies and technologies aimed at enhanced pain management. This initiative specifically seeks applications from small businesses that propose innovative solutions, including non-addictive medications, devices for objective pain measurement, and new screening tools, to address the national opioid crisis. The funding opportunity allows for grants of up to $8 million per year, with budget limits set at $275,766 for Phase I and $1,838,436 for Phase II, and applications are due by April 4, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-NS-23-006.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the HEAL Initiative aimed at addressing the opioid crisis by funding Small Business Innovation Research (SBIR) projects focused on enhancing pain management. The funding opportunity encourages applications that propose innovative therapies, non-addictive medications, devices for pain measurement, and screening tools under the related FOA number RFA-NS-23-006. The initiative seeks solutions that bypass the need for opioids, which have led to addiction and overdose issues. Key details include eligibility criteria limited to U.S. small businesses, funding of up to $8 million per year for 5-15 awards, and budget limits of $275,766 for Phase I and $1,838,436 for Phase II. The emphasis is on novel non-addictive treatments and the development of technologies for pain assessment. The NIH encourages early applications to ensure compliance with submission requirements. Ultimately, this initiative aims to foster scientific advancements that will significantly improve pain management while addressing public health concerns surrounding opioid use.
    Similar Opportunities
    HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at developing innovative therapies and technologies for enhanced pain management. This initiative specifically seeks applications from small businesses focused on creating non-addictive pain treatment alternatives, objective pain measurement tools, and new screening methodologies to address the national opioid crisis. With an annual funding projection of up to $8 million for 5-15 awards, eligible applicants must be U.S. small businesses, and the application deadline is set for April 4, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-006.html.
    HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of non-addictive analgesic therapeutics, specifically small molecules and biologics, aimed at treating pain. The initiative seeks to accelerate the optimization and transition of promising therapeutic candidates to Phase I clinical trials, requiring applicants to demonstrate a compelling biological rationale and suitable assays for their projects. This funding is crucial for addressing the needs of over 25 million Americans suffering from chronic pain while providing alternatives to opioids. Approximately $11 million is anticipated for distribution across four awards in FY 2024, with applications due by January 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices," aimed at addressing the opioid epidemic by promoting innovative research into alternative pain management solutions. This initiative seeks interdisciplinary research teams composed of multiple Principal Investigators (PDs/PIs) to explore the mechanisms of action of FDA-approved medical devices designed for pain relief, with the goal of optimizing therapeutic outcomes and enhancing understanding of device-based therapies. With over 25 million Americans suffering from chronic pain, this funding is critical for developing safe and effective pain treatment options that minimize addiction risks. Interested applicants can apply for grants with an award ceiling of $1.5 million, and proposals are due by June 9, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-028.html.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative for the development of clinical-grade diagnostic and therapeutic devices aimed at treating pain and addressing opioid use disorder (OUD). This grant seeks to support the creation of non-addictive device-based technologies, advancing them from early development to preclinical stages suitable for FDA approval, with a focus on demonstrating treatment efficacy through credible neural targets. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, for-profit entities, and tribal governments, with funding available for up to three years and a maximum budget of $750,000 annually. Interested parties should note that the application deadline is June 17, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at understanding individual differences in human pain conditions through the R01 grant mechanism. This initiative seeks research proposals that focus on the holistic understanding of pain variability among individuals, emphasizing the collection of clinical and preclinical data to inform personalized pain management strategies. The program is particularly relevant in the context of addressing the ongoing opioid crisis and aims to foster innovative, evidence-based solutions for pain treatment by encouraging multidisciplinary approaches and patient engagement. Approximately $4 million is available to support 3-4 awards, with applications due by February 6, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, aimed at understanding individual differences in human pain conditions through the R01 grant mechanism. This initiative seeks to support research that holistically examines inter-individual differences in pain experiences, focusing on personalized pain management strategies and the collection of clinical and preclinical data. The funding is particularly important for advancing knowledge on the biological and psychosocial factors influencing pain sensitivity and treatment responses, especially in underserved populations. NIH plans to allocate approximately $4 million for 3-4 awards, with each application eligible for up to $650,000 in direct costs over a five-year period. Interested applicants must submit their proposals by February 6, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis," aimed at supporting research that translates findings into practical solutions for addressing the overdose crisis. This initiative encourages applications from a diverse range of organizations, including educational institutions and nonprofits, with a focus on developing stigma-free, patient-centered systems for addiction recovery and improving the quality of addiction treatment services. The NIH plans to commit approximately $10 million to fund grants, with an expected award ceiling of $750,000 for up to 12 awards, and applications will be accepted starting February 20, 2025, with a closing date of March 20, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-077.html.